Podcast: Top Researcher Says Antibodies Key to Unleashing Cancer-Killing T-Cells
By Marc Dresner, IBC Life Sciences
The “cure” for cancer may already reside in the human body. It just needs to be activated.
|Dr. Louis M. Weiner|
Sound a little crazy? That’s fine by Weiner.
Thirty years ago, his colleagues said he was nuts to dedicate himself to anything as “radical and unpromising” as using antibodies to treat cancer; today they constitute the backbone therapies for many cancers.
“We are really on the verge of breaking down the defenses of cancer that have been erected to avoid immune destruction,” said Dr. Weiner.
In this podcast interview for Inside Antibody Engineering, Dr. Louis Weiner shares his thoughts on the state of unconjugated antibodies in cancer treatment, what the future holds for antibody drug conjugates for cancer treatment and how the immune system may be deployed to fight cancer.
Listen to the podcast or download a transcript here!
Editor’s note: Dr. Louis Weiner will speak on “Targeting Cancer’s Fragile Strength with Immunotherapy” at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.
Click here for an agenda.
Or for more information visit: www.ibclifesciences.com/antibodyeng
(Ps. SAVE $100 when you register with code D15172BLOG!)
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at firstname.lastname@example.org. Follow him @mdrezz.
Share this article with your social network, just click below to share now!